

## Renewal of Provisional Consent to the Distribution of a Medicine

Pursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health hereby renews the provisional consent to the sale, supply or use in New Zealand of the medicine set out in the Schedule hereto:

### Schedule

|                             |   |
|-----------------------------|---|
| <b>Product:</b>             | <b>Panvax vaccine</b>                       |
| <i>Active Ingredient:</i>   | Influenza Virus Type A haemagglutinin 30mcg |
| <i>Dosage Form:</i>         | Suspension for injection                    |
| <i>New Zealand Sponsor:</i> | Seqirus (NZ) Limited                        |
| <i>Manufacturer:</i>        | Seqirus Pty Limited, Melbourne, Australia   |

*Note:* This consent is given subject to the following condition:

- The vaccine may only be marketed or distributed in accordance with the directives contained in the current version of the New Zealand Influenza Pandemic Action Plan.

*Note:* This renewed consent is valid for two years from 6 March 2022.

Dated this 4th day of March 2022.

CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).